1. Home
  2. BLRX vs AWX Comparison

BLRX vs AWX Comparison

Compare BLRX & AWX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • AWX
  • Stock Information
  • Founded
  • BLRX 2003
  • AWX 1998
  • Country
  • BLRX Israel
  • AWX United States
  • Employees
  • BLRX N/A
  • AWX N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • AWX Environmental Services
  • Sector
  • BLRX Health Care
  • AWX Utilities
  • Exchange
  • BLRX Nasdaq
  • AWX Nasdaq
  • Market Cap
  • BLRX 12.2M
  • AWX 13.6M
  • IPO Year
  • BLRX 2011
  • AWX 1998
  • Fundamental
  • Price
  • BLRX $3.10
  • AWX $2.84
  • Analyst Decision
  • BLRX Buy
  • AWX
  • Analyst Count
  • BLRX 2
  • AWX 0
  • Target Price
  • BLRX $26.00
  • AWX N/A
  • AVG Volume (30 Days)
  • BLRX 26.4K
  • AWX 15.5K
  • Earning Date
  • BLRX 05-27-2025
  • AWX 05-07-2025
  • Dividend Yield
  • BLRX N/A
  • AWX N/A
  • EPS Growth
  • BLRX N/A
  • AWX N/A
  • EPS
  • BLRX N/A
  • AWX 0.34
  • Revenue
  • BLRX $28,940,000.00
  • AWX $83,795,000.00
  • Revenue This Year
  • BLRX N/A
  • AWX N/A
  • Revenue Next Year
  • BLRX N/A
  • AWX N/A
  • P/E Ratio
  • BLRX N/A
  • AWX $8.14
  • Revenue Growth
  • BLRX 502.92
  • AWX 3.58
  • 52 Week Low
  • BLRX $2.85
  • AWX $2.00
  • 52 Week High
  • BLRX $35.60
  • AWX $3.99
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 41.70
  • AWX 41.76
  • Support Level
  • BLRX $3.01
  • AWX $2.48
  • Resistance Level
  • BLRX $3.61
  • AWX $3.02
  • Average True Range (ATR)
  • BLRX 0.22
  • AWX 0.20
  • MACD
  • BLRX 0.02
  • AWX -0.01
  • Stochastic Oscillator
  • BLRX 32.89
  • AWX 42.35

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About AWX Avalon Holdings Corporation

Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.

Share on Social Networks: